Table 1. Patient and treatment characteristics.
| No.(%) | ||
|---|---|---|
| No. of patients | 89 (100) | |
| Sex | Male/Female | 65 (73.0)/24 (27.0) |
| Age, years | Median/Range | 68/36-87 |
| Viral hepatitis | HBV | 46 (51.7) |
| HCV | 28 (31.5) | |
| Both | 3 (3.4) | |
| None | 12 (13.5) | |
| Recurrent tumor | Yes/ No | 54 (60.7)/35(39.3) |
| Largest tumor size, cm | Median/Range | 6.2/1.2–18.5 |
| Sum of largest diameters of tumor, cm | Median/Range | 6.6/1.5–23.5 |
| Tumor number | Solitary/Multiple | 31/58 |
| Macrovascular invasion | Yes/No | 44 (49.4)/45 (50.6) |
| mPVTT | Yes/No | 23 (25.8)/66 (74.2) |
| Extrahepatic spread | Yes/No | 26 (29.2)/63 (70.8) |
| TNM stage | I | 7 (7.9) |
| II | 13 (14.6) | |
| IIIA/ IIIB/ IIIC | 7 (7.9)/ 34 (38.2)/2 (2.2) | |
| IVA/ IVB | 11 (12.4)/15 (16.9) | |
| ECOG performance status | 0–1 | 76 (85.4) |
| 2 | 13 (14.6) | |
| AFP Level | < 400/≥ 400 | 49 (55.1)/40 (44.9) |
| CTP Classification | A/B | 69 (77.5)/20 (22.5) |
| Combined systemic treatment | No | 50 (56.2) |
| Thalidomide | 14 (15.7) | |
| Sorafenib | 23 (25.8) | |
| Tegafur/Uracil | 2 (2.2) | |
Abbreviation: SABR = stereotactic ablative radiotherapy; HBV = hepatitis B virus; HCV = hepatitis C virus; mPVTT = main portal vein tumor thrombosis; ECOG = Eastern Cooperative Oncology Group; AFP = α-fetoprotein; CTP = Child-Turcotte-Pugh liver function scale; TACE = Transarterial chemoembolization